Meropenem Dosing for CNS Infections in Adults
For CNS infections caused by suspected ESBL-producing Enterobacteriaceae, administer meropenem 2 grams IV every 8 hours as a 3-hour extended infusion for 21 days. 1
Standard Dosing Regimen
The UK Joint Specialist Societies guideline specifically addresses meropenem for CNS infections when ESBL organisms are suspected:
- Dose: 2 grams IV every 8 hours
- Duration: 21 days
- Indication: High suspicion of ESBL-producing Enterobacteriaceae in blood or CSF 1
This recommendation comes from the 2016 UK meningitis guidelines, which provide the most specific guidance for meropenem in CNS infections among the available evidence.
Optimizing CNS Penetration
Extended infusion (3-hour infusion) is strongly preferred over standard 30-minute infusions for CNS infections. The rationale is critical:
- CSF penetration of meropenem is only 6.4% even with inflamed meninges 2
- Extended infusions maintain concentrations above the MIC for 100% of the dosing interval in CSF 2
- Standard 30-minute infusions may achieve inadequate CSF levels, particularly for organisms with MIC ≥0.25 mg/L 3
A prospective study in neurocritical care patients demonstrated that doses up to 8-10 g/day may be required to achieve adequate CSF concentrations for less susceptible organisms, especially in patients with augmented renal clearance 3. However, this exceeds FDA-approved dosing and should be reserved for refractory cases with infectious disease consultation.
Renal Function Adjustments
Dosing must be adjusted based on creatinine clearance:
| CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >50 | 2 g | Every 8 hours |
| 26-50 | 2 g | Every 12 hours |
| 10-25 | 1 g | Every 12 hours |
| <10 | 1 g | Every 24 hours |
Critical caveat: These renal adjustments are based on FDA labeling for non-CNS infections. For CNS infections with impaired renal function, the balance between adequate CNS penetration and toxicity becomes more complex.
Special Populations
Augmented Renal Clearance
Critically ill patients with CrCl ≥90 mL/min often require higher doses or continuous infusion to maintain therapeutic levels 5. Standard regimens are suboptimal in this population. Consider:
- Increased dose frequency
- Extended infusion duration (3 hours)
- Continuous infusion after loading dose
Continuous Renal Replacement Therapy (CRRT)
For patients on CRRT, 750 mg every 8 hours achieves appropriate pharmacodynamic targets for most pathogens 6. Meropenem is significantly cleared by CRRT, with clearance rates varying by:
- CRRT modality (CVVH vs CVVHDF)
- Effluent flow rates
- Residual renal function 7
Pharmacodynamic Targets
The therapeutic goal is maintaining free drug concentrations above the MIC for 40% of the dosing interval (40% fT>MIC) as a minimum, but for CNS infections, 100% fT>MIC is preferred given the critical nature of these infections and limited CNS penetration 3, 2.
For organisms with higher MICs (≥0.25 mg/L), achieving 40% fT>4×MIC may be necessary, which often requires doses exceeding standard recommendations 6.
Therapeutic Drug Monitoring
TDM is strongly recommended for CNS infections 7, 8. Measure:
- Plasma trough concentrations for intermittent dosing
- Steady-state concentrations for continuous infusion
- CSF concentrations when possible (via lumbar drain or ventricular drain) 7
Timing: Obtain levels at 24-48 hours after treatment initiation and after any significant clinical change (renal function, fluid status, CRRT initiation) 7.
Target CSF concentrations should exceed the pathogen's MIC throughout the dosing interval 3.
Common Pitfalls
- Using standard 30-minute infusions: This results in subtherapeutic CSF levels for much of the dosing interval
- Failing to adjust for augmented renal clearance: Critically ill patients often have enhanced drug elimination
- Not considering organism MIC: Higher MICs require more aggressive dosing
- Inadequate duration: The guideline specifies 21 days for Enterobacteriaceae CNS infections, not the shorter durations used for other pathogens 1
Alternative Considerations
While the FDA label approves meropenem for pediatric bacterial meningitis (40 mg/kg every 8 hours, maximum 2 grams) 4, it is NOT FDA-approved for adult CNS infections. The use in adults is based on guideline recommendations and pharmacokinetic principles rather than specific FDA approval for this indication.
For MRSA CNS infections, meropenem is not appropriate—vancomycin remains the drug of choice 9.